← Browse by Condition
Medical Condition
nsclc
Total Trials
16
Recruiting Now
16
Trial Phases
Phase 1, Phase 2, EARLY_Phase 1
NCT05787587 Phase 1
Recruiting
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Enrollment
216 pts
Location
United States
Sponsor
IDEAYA Biosciences
NCT05657873 Phase 2
Recruiting
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
Enrollment
68 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
NCT07349537 Phase 1
Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Enrollment
574 pts
Location
United States
Sponsor
Revolution Medicines, Inc.
NCT05987345
Recruiting
Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer
Enrollment
10 pts
Location
China
Sponsor
Energenx Medical LTD.
NCT06339242 Phase 2
Recruiting
A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis
Enrollment
30 pts
Location
China
Sponsor
Jiangsu Province Nanjing Brain...
NCT06789172 Phase 1
Recruiting
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Enrollment
166 pts
Location
United States, Austr...
Sponsor
Epkin
NCT06317558
Recruiting
Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy
Enrollment
4,000 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
NCT07274813 EARLY_Phase 1
Recruiting
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors
Enrollment
254 pts
Location
China
Sponsor
Shanghai Henlius Biotech
NCT07388771
Recruiting
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）
Enrollment
500 pts
Location
China
Sponsor
Qian Chu
NCT07010419 Phase 3
Recruiting
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）
Enrollment
338 pts
Location
China
Sponsor
Allist Pharmaceuticals, Inc.
NCT04712877
Recruiting
Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers
Enrollment
1,000 pts
Location
United States
Sponsor
Lung Cancer Mutation Consortiu...
NCT06043817 Phase 1, Phase 2
Recruiting
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Enrollment
251 pts
Location
United States, Franc...
Sponsor
Pierre Fabre Medicament
NCT04585750 Phase 1, Phase 2
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Enrollment
300 pts
Location
United States, Austr...
Sponsor
PMV Pharmaceuticals, Inc
NCT04686682 Phase 1, Phase 2
Recruiting
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Enrollment
152 pts
Location
China
Sponsor
Jacobio Pharmaceuticals Co., L...
NCT06844474 Phase 2
Recruiting
A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC
Enrollment
300 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
NCT06738160 Phase 2
Recruiting
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Enrollment
27 pts
Location
China
Sponsor
Fudan University